Glucose Intolerance

• 

  Subject Areas on Research

  • A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism. 
  • A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk. 
  • Abrogation of adenosine A1 receptor signalling improves metabolic regulation in mice by modulating oxidative stress and inflammatory responses. 
  • Adipose tissue hyaluronan production improves systemic glucose homeostasis and primes adipocytes for CL 316,243-stimulated lipolysis. 
  • Adiposity, cardiometabolic risk, and vitamin D status: the Framingham Heart Study. 
  • Adrb2 controls glucose homeostasis by developmental regulation of pancreatic islet vasculature. 
  • Age-dependent impairment of glucose tolerance in the 3xTg-AD mouse model of Alzheimer's disease. 
  • Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis. 
  • Association between triclocarban and triclosan exposures and the risks of type 2 diabetes mellitus and impaired glucose tolerance in the National Health and Nutrition Examination Survey (NHANES 2013-2014). 
  • BCAA Supplementation in Mice with Diet-induced Obesity Alters the Metabolome Without Impairing Glucose Homeostasis. 
  • BCAA catabolism in brown fat controls energy homeostasis through SLC25A44. 
  • Baseline characteristics of participants in the Pre-Diabetes Interventions and Continued Tracking to Ease-out Diabetes (Pre-DICTED) Program. 
  • Beta-cell function, insulin sensitivity, and glucose tolerance in obese diabetic and nondiabetic adolescents and young adults. 
  • Cafeteria diet is a robust model of human metabolic syndrome with liver and adipose inflammation: comparison to high-fat diet. 
  • Calcium/calmodulin-dependent protein kinase kinase 2 regulates macrophage-mediated inflammatory responses. 
  • Cardiovascular risk factors and retinal microvascular signs in an adult Japanese population: the Funagata Study. 
  • Carnitine insufficiency caused by aging and overnutrition compromises mitochondrial performance and metabolic control. 
  • ChREBP regulates fructose-induced glucose production independently of insulin signaling. 
  • Comparison of insulin sensitivity assessment indices with euglycemic-hyperinsulinemic clamp data after a dietary and exercise intervention in older adults. 
  • Delayed fracture healing and increased callus adiposity in a C57BL/6J murine model of obesity-associated type 2 diabetes mellitus. 
  • Deletion of CaMKK2 from the liver lowers blood glucose and improves whole-body glucose tolerance in the mouse. 
  • Deletion of GαZ protein protects against diet-induced glucose intolerance via expansion of β-cell mass. 
  • Depletion of circulating progenitor cells precedes overt diabetes: a substudy from the VA enhanced fitness trial. 
  • Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults. 
  • Disorders of glucose homeostasis in young adults treated with total body irradiation during childhood: a pilot study. 
  • Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. 
  • Divalent metal transporter 1 regulates iron-mediated ROS and pancreatic β cell fate in response to cytokines. 
  • Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling. 
  • Duodenal-jejunal exclusion improves glucose tolerance in the diabetic, Goto-Kakizaki rat by a GLP-1 receptor-mediated mechanism. 
  • Effect of ramipril on the incidence of diabetes. 
  • Effect of vertical sleeve gastrectomy in melanocortin receptor 4-deficient rats. 
  • Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH. 
  • Effects of changes in potassium with valsartan use on diabetes risk: Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. 
  • Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. 
  • Enhanced Glucose Control Following Vertical Sleeve Gastrectomy Does Not Require a β-Cell Glucagon-Like Peptide 1 Receptor. 
  • Evidence of a relationship between infant birth weight and later diabetes and impaired glucose regulation in a Chinese population. 
  • G(s)alpha deficiency in skeletal muscle leads to reduced muscle mass, fiber-type switching, and glucose intolerance without insulin resistance or deficiency. 
  • Genetic Abrogation of Adenosine A3 Receptor Prevents Uninephrectomy and High Salt-Induced Hypertension. 
  • Gestational retinal microvasculature and the risk of 5 year postpartum abnormal glucose metabolism. 
  • Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. 
  • Glucose challenge test screening for prediabetes and undiagnosed diabetes. 
  • Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the Baltimore Longitudinal Study of Aging. 
  • Glycerate from intestinal fructose metabolism induces islet cell damage and glucose intolerance. 
  • Hemoglobin A1c and postpartum abnormal glucose tolerance among women with gestational diabetes mellitus. 
  • Hepatic hexokinase domain containing 1 (HKDC1) improves whole body glucose tolerance and insulin sensitivity in pregnant mice. 
  • High-density lipoprotein maintains skeletal muscle function by modulating cellular respiration in mice. 
  • Hyperphagia and increased fat accumulation in two models of chronic CNS glucagon-like peptide-1 loss of function. 
  • Hypothalamic CaMKK2 contributes to the regulation of energy balance. 
  • Impaired glucose tolerance in midlife and longitudinal changes in brain function during aging. 
  • Impaired glucose tolerance, but not impaired fasting glucose, is associated with retinopathy in Japanese population: the Funagata study. 
  • Impaired insulin secretion and enhanced insulin sensitivity in cholecystokinin-deficient mice. 
  • Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. 
  • Increased lipid accumulation and insulin resistance in transgenic mice expressing DGAT2 in glycolytic (type II) muscle. 
  • Inflammation and glucose intolerance: a prospective study of gestational diabetes mellitus. 
  • Inhibition of the gut enzyme intestinal alkaline phosphatase may explain how aspartame promotes glucose intolerance and obesity in mice. 
  • Insulin and glucose homeostasis in childhood cancer survivors treated with abdominal radiation: A pilot study. 
  • Insulin reverses the high-fat diet-induced increase in brain Aβ and improves memory in an animal model of Alzheimer disease. 
  • Interaction of GLP-1 and Ghrelin on Glucose Tolerance in Healthy Humans. 
  • International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial. 
  • Is peripheral neuropathy associated with retinopathy and albuminuria in individuals with impaired glucose metabolism? The 1999-2000 AusDiab. 
  • Lipoprotein response to exercise training and a low-fat diet in older subjects with glucose intolerance. 
  • Lower levels of circulating progenitor cells are associated with low physical function and performance in elderly men with impaired glucose tolerance: a pilot substudy from the VA Enhanced Fitness trial. 
  • Meal feeding improves oral glucose tolerance in male rats and causes adaptations in postprandial islet hormone secretion that are independent of plasma incretins or glycemia. 
  • Metabolic syndrome: definition, pathophysiology, and mechanisms. 
  • Mice with chronically increased circulating ghrelin develop age-related glucose intolerance. 
  • Neurotrophin Signaling Is Required for Glucose-Induced Insulin Secretion. 
  • Noncardiovascular deaths are more common than cardiovascular deaths in patients with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. 
  • Oral L-arginine stimulates GLP-1 secretion to improve glucose tolerance in male mice. 
  • Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial. 
  • Plasma epinephrine predicts fasting glucose in centrally obese African-American women. 
  • Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. 
  • Prevalence of diabetes and impaired fasting glucose in Poland--the NATPOL 2011 Study. 
  • Prevalences of type 2 diabetes, the insulin resistance syndrome, and coronary heart disease in an elderly, biethnic population. 
  • Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study. 
  • Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. 
  • Rapid deterioration of insulin secretion in obese adolescents preceding the onset of type 2 diabetes. 
  • Relationship of retinal vascular caliber with diabetes and retinopathy: the Multi-Ethnic Study of Atherosclerosis (MESA). 
  • Restoration of the serum level of SERPINF1 does not correct the bone phenotype in Serpinf1 null mice. 
  • Retinal fractal dimension is increased in persons with diabetes but not impaired glucose metabolism: the Australian Diabetes, Obesity and Lifestyle (AusDiab) study. 
  • Reversal of diet-induced glucose intolerance by hepatic expression of a variant glycogen-targeting subunit of protein phosphatase-1. 
  • Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). 
  • Role of Mitochondrial Oxidative Stress in Glucose Tolerance, Insulin Resistance, and Cardiac Diastolic Dysfunction. 
  • Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. 
  • Role of insulin-like growth factor-binding protein 5 (IGFBP5) in organismal and pancreatic beta-cell growth. 
  • SIRT3 Directs Carbon Traffic in Muscle to Promote Glucose Control. 
  • Screening for metabolic and reproductive complications in obese children and adolescents. 
  • Sex-dimorphic genetic effects and novel loci for fasting glucose and insulin variability. 
  • Syntaxin 4 Expression in Pancreatic β-Cells Promotes Islet Function and Protects Functional β-Cell Mass. 
  • Tamoxifen Improves Glucose Tolerance in a Delivery-, Sex-, and Strain-Dependent Manner in Mice. 
  • The association between maternal glucose concentration and child BMI at age 3 years. 
  • The carboxypeptidase E knockout mouse exhibits endocrinological and behavioral deficits. 
  • The role of β cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs. 
  • Urinary F2-isoprostanes as a biomarker of reduced risk of type 2 diabetes. 
  • Variation in Postpartum Glycemic Screening in Women With a History of Gestational Diabetes Mellitus. 
  • Venous thromboembolism and cardiovascular risk: results from the NAVIGATOR trial. 
  • Zfp423 Maintains White Adipocyte Identity through Suppression of the Beige Cell Thermogenic Gene Program. 
  • β-Cell Function Over Time in Adolescents With New Type 2 Diabetes and Obese Adolescents Without Diabetes. 
  • β-Cell-specific ablation of sirtuin 4 does not affect nutrient-stimulated insulin secretion in mice.